Novus Scientific and Singapore Association of Plastic Surgeons (SAPS) Host the Inaugural Event of 'SOFTISSUE - The Issue of Soft Tissue,' Featuring James J. Chao, M.D., FACS, Professor of Plastic Surgery and Orthopedic Surgery, University of California, San Diego

SINGAPORE, Nov. 3, 2010 /PRNewswire/ -- Singapore company Novus Scientific Pte. Ltd today announced the successful hosting of Asia's 1st "SOFTISSUE – The Issue of Soft Tissue" educational series, together with the Singapore Association of Plastic Surgeons (SAPS) on 1st November 2010.

This inaugural event featured James J. Chao, M.D., FACS, who spoke on "Technological Innovations in Plastic Surgery," which focused on the latest advances in breast reconstruction & fat grafting. Dr. Chao is currently Professor of Plastic Surgery and Orthopedic Surgery at the University of California, San Diego (UCSD) Medical Centre. Attendees consisted of Plastic & General Surgeons from Singapore and the region, as well as select government agencies and members of the health media. The venue was at the Novus Restaurant, housed in the historical National Museum of Singapore.

"I am honored to be invited as the 1st speaker of SOFTISSUE, as it provides not only a great platform for U.S. Plastic Surgeons such as myself to interact and share clinical best practices with surgeons of SAPS, but also an opportunity to collaborate on future clinical studies, which may bring tremendous benefits to patients worldwide," said James J. Chao, M.D., FACS, Professor of Plastic Surgery & Professor of Orthopedic Surgery, (UCSD).

"Novus Scientific is a proud supporter of the 1st SOFTISSUE, together with SAPS, which brings together the top Plastic, Aesthetic and Reconstructive Surgeons in Singapore and the U.S. for an educational meeting of minds," said Thomas Engstrom, CEO & President of Novus Scientific. "We plan to bring SOFTISSUE to the U.S. as well as to Europe and beyond in the years to come."

Novus Scientific is currently supporting a clinical study on TRAM Flap donor site reinforcement using TIGR^® Matrix Surgical Mesh. Asia's first patient was enrolled on 21st October 2010 at the National University Hospital Singapore. Link http://bit.ly/btihfu

TIGR^® Matrix is the World's 1st Long-Term Resorbable Synthetic Mesh. U.S. FDA cleared TIGR^® Matrix Surgical Mesh for use in reinforcement of soft tissues where weakness exists in February 2010.

About Novus Scientific

Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable synthetic medical devices. Global HQ is in Singapore while European Headquarters and the core R&D function are in Uppsala, Sweden. The company's roots are Swedish as all the founders of Novus Scientific are previous owners / senior managers / members of the soft tissue-engineering project within Uppsala-based, Radi Medical Systems AB (now owned by St. Jude Medical Inc). The US Division, Novus Scientific, Inc. is headquartered near Boston, one of the world's foremost medical research cities. From this hub, Novus Scientific, Inc. will distribute TIGR^® Matrix Surgical Mesh throughout the United States.

TIGR^® is a trademark of Novus Scientific Pte. Ltd

Media contact: Tac-Whei Ong ([email protected]) - tel: +65 9179 6661

SOURCE Novus Scientific Pte. Ltd